Moffitt Medical GroupSenior Adult Oncology Program 12902 Usf Magnolia Dr, Tampa, FL 33612 (813)7456769 (phone), (813)7453730 (fax)
Education:
Medical School New York University School of Medicine Graduated: 1980
Procedures:
Chemotherapy
Conditions:
Melanoma Rectal, Abdomen, Small Intestines, or Colon Cancer Abdominal Hernia Acute Pancreatitis Acute Renal Failure
Languages:
English Spanish
Description:
Dr. Weber graduated from the New York University School of Medicine in 1980. He works in Tampa, FL and specializes in Medical Oncology. Dr. Weber is affiliated with Moffitt Cancer Center.
Dr. Weber graduated from the Pennsylvania State University College of Medicine in 1993. He works in Ephrata, PA and specializes in Family Medicine. Dr. Weber is affiliated with WellSpan Ephrata Community Hospital.
Mr. Weber works in Raleigh, NC and 1 other location and specializes in Pain Management. Mr. Weber is affiliated with Duke Raleigh Hospital and Wakemed Raleigh Campus.
Canalys since May 2013
Director of Accounts, US
Transfix - Manhattan Beach, CA since Jul 2010
Co-Founder
Gartner - Stamford, CT Nov 2008 - Jul 2010
Account Executive
Johnson & Johnson - Tulsa, Oklahoma Area Jun 2004 - Jun 2008
Professional Sales Representative
GolinHarris - Tokyo, Japan Feb 2003 - Apr 2003
Executive Assistant
Education:
Georgetown University - The McDonough School of Business 2000 - 2004
BSBA, Finance, International Business, Japanese
上智大学 / Sophia University 2003 - 2003
Skills:
Strategy Marketing New Business Development Start Ups Business Strategy Management Business Development Strategic Partnerships Entrepreneurship Go To Market Strategy Sales Operations Marketing Strategy Integrated Marketing Executive Management Sales Entrepreneur Crm Competitive Analysis Social Media Product Marketing Strategic Planning Account Management Analysis Enterprise Software Saas Salesforce.com Leadership Social Media Marketing Sales Management Project Management Analytics Digital Marketing Lead Generation Customer Service Product Management Program Management Solution Selling Market Research International Business Microsoft Excel E Commerce Public Relations Cross Functional Team Leadership Consulting Advertising
Interests:
Mobile Groceries Sports Sporting Goods Health Logistics Children Predictive Analytics Clean Technology Biotechnology Market Research Environment Education Science and Technology Advertising Medical Devices Mobile Advertising Golf Equipment Transportation Poverty Alleviation Disaster and Humanitarian Relief Economic Empowerment Logistics Company Medical Animal Welfare Big Data Analytics Small and Medium Businesses
Languages:
Japanese Spanish
Awards:
Rookie of the Year Ortho-McNeil-Janssen Pharmaceuticals, Inc. Kansas City Region Rookie of the Year Award, 2005 #1 National Sales Rank out of 450 associates Ortho-McNeil-Janssen Pharmaceuticals, Inc. Gartner Winner's Circle Obtained 385% of new business quota and 120% of total sales quota with a $1.3M total contract value under management for 2009 Johnson and Johnson Sales Leadership Development Program Program designed for new graduates to excel in a rapidly growing sales area and be prepared for broader responsibility across a range of related disciplines. Structured training and hands-on experience help participants accelerate their career growth.
Carole Anne Vogt - Budd Lake NJ, US Gladys Odette Sierra-Gomez - Woodbridge NJ, US Jeffrey Thomas Weber - Lake Zurich IL, US Elizabeth A. McDermott - Verona NJ, US Douglas H. Philipsen - Hackettstown NJ, US
A resealable closure for packages is provided which has a package integrity feature. The closure includes a two-ply material having an inner film layer and an outer film layer, forming a top of container. The outer film layer has a sealing panel completely covering a first panel and a second panel of the inner film layer. The sealing panel is permanently attached to the first panel and is releasably affixed a portion of the inner film layer around the perimeter of the first panel to form an opening in the top when the sealing panel with affixed first panel is peeled back from the top. The sealing panel is resealable against the top to seal the opening when the sealing panel is moved back against the top. The package integrity feature comprises the second panel of the inner layer which separates from the sealing panel to indicate that the container has been previously opened.
Carole A. Cole - Budd Lake NJ, US Jeffrey Thomas Weber - Lake Zurich IL, US
Assignee:
Kraft Foods Global Brands LLC - Deerfield IL
International Classification:
B65D 33/00 B65D 33/14 B65D 33/04
US Classification:
383203, 383 5, 383211, 383106
Abstract:
A resealable closure for a container in which package integrity is indicated by a structure which breaks and/or produces an audible sound when the resealable closure is opened for a first time. The package integrity feature, in one form includes at least one strip initially affixed to two portions which comprise the resealable closure so that upon opening the resealable closure for a first time, at least one of the strips breaks, thereby producing the audible sound. The strips may include a weakened portion such as a narrowing. Integrity of the package is indicated by an intact strip viewable upon opening the resealable closure and conversely, a broken or non-intact strip would indicate that the resealable closure has been previously opened. Package integrity may also be shown by a movable second panel or movable die cut tab portions.
Assessment Of Ctla-4 Polymorphisms In Ctla-4 Blockade Therapy
Geoffrey Nichol - Short Hills NJ, US Michael Yellin - Upper Montclair NJ, US Steven Fischkoff - Short Hills NJ, US Jeffrey Weber - Los Angeles CA, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The invention provides methods for predicting responsiveness of a subject to therapy with a CTLA-4 blocking agent. The methods involve assaying for at least one CTLA-4 polymorphism in the subject and predicting responsiveness of the subject to therapy with a CTLA-4 blocking agent based on presence or absence of a CTLA-4 polymorphic allele in the subject. The methods can further comprise selecting a treatment regimen with a CTLA-4 blocking agent in a subject based upon presence or absence of a CTLA-4 polymorphic allele in the subject. The methods can further comprise administering a CTLA-4 blocking agent to the subject according to the selected treatment regimen. Kits comprising a CTLA-4 blocking agent and means for assaying one or more CTLA-4 polymorphisms, optionally including a vaccine, are also provided.
Gladys Sierra-Gomez - Woodbridge NJ, US Eva Peters - Cedar Grove NJ, US Thomas Tedeschi - Brewster NY, US Jeffrey Weber - Lake Zurich IL, US Stuart Paterson - Fox River Grove IL, US
International Classification:
B65D 17/34
US Classification:
220359200, 220270000
Abstract:
A polygonal shaped container is provided which includes a wrapper surrounding a food product. The shape of the container is defined by either a frame containing a food product or rigid material incorporated with the wrapper. Access to contents in the container is provided by withdrawing a resealable sealing layer sealed to the top or side surface of the container and withdrawing the sealing layer from the container or by pivoting a rigid lid away from the top of the container.
Deborah Lyzenga - Long Valley NJ, US Jeffrey Thomas Weber - Lake Zurich IL, US Scott William Huffer - Hartsville SC, US Benjamin Michael Davis - Columbia SC, US
International Classification:
B65D 43/02
US Classification:
220214, 2203591
Abstract:
A resealable closure for a container in which package integrity is indicated by a structure which connects the closure to a remaining portion of the container which must be broken in order to gain access to the contents of the container for a first time. The package integrity feature, in one form, includes a structure associated with the closure, wherein upon opening the closure for a first time, the structure stretches, increasing a length of the structure until the structure eventually breaks, leaving one or both residual ends of the broken structure rippled or curved upward from the remainder of the container. In one alternative form, the structure is associated with a pull tab of the sealing panel, which comprises the closure, whereby either the structure must be broken first, prior to pulling back the sealing panel, or while pulling back the sealing panel for a first time, the structure breaks, prior to gaining access to the contents therein. Advantageously, the package integrity feature is integrally formed with the closure and a remaining portion of the container. Integrity of the package is indicated by visually observing an intact breakable structure.
Reclosable Flexible Packaging And Methods For Manufacturing Same
Deborah A. LYZENGA - Long Valley NJ, US Jeffrey Thomas WEBER - Lake Zurich IL, US Leonard SCAROLA - Cary NC, US Rachel LEICHTE - Glen Rock NJ, US Marty GOLDEN - Highland Park NJ, US Paul E. DOLL - Madison WI, US
Flexible film packages having a partial, initial seal against ambient atmosphere and are easily openable and reclosable. The flexible film packages are generally resealable to extend the shelf-life or freshness of products contained therein once the package is initially opened. By one approach, the flexible film has two opposing edge portions that meet to form a longitudinal seal extending from a first end seal to a second end seal. The flexible film may have a score that defines a package opening. An elongated closure layer may extend over the score and may extend from a first end seal to a second end seal and within the opposing edge portions that form the longitudinal seal. The elongated closure layer may have a tack-free gripping portion used to release at least a portion of the elongated closure from the flexible film to form the package opening.
Carole Anne Vogt - Budd Lake NJ, US Gladys Odette Sierra-Gomez - Woodbridge NJ, US Jeffrey Thomas Weber - Lake Zurich IL, US Elizabeth A. McDermott - Verona NJ, US Douglas H. Philipsen - Hackettstown NJ, US
International Classification:
B65D 77/30 B65D 51/20
US Classification:
383 5, 383203, 383211, 2202583
Abstract:
A resealable closure for packages is provided which has a package integrity feature. The closure includes a two-ply material having an inner film layer and an outer film layer, forming a top of container. The outer film layer has a sealing panel completely covering a first panel and a second panel of the inner film layer. The sealing panel is permanently attached to the first panel and is releasably affixed a portion of the inner film layer around the perimeter of the first panel to form an opening in the top when the sealing panel with affixed first panel is peeled back from the top. The sealing panel is resealable against the top to seal the opening when the sealing panel is moved back against the top. The package integrity feature comprises the second panel of the inner layer which separates from the sealing panel to indicate that the container has been previously opened.
A resealable closure for a container in which package integrity is indicated by a structure which breaks and/or produces an audible sound when the resealable closure is opened for a first time. The package integrity feature, in one form includes at least one strip initially affixed to two portions which comprise the resealable closure so that upon opening the resealable closure for a first time, at least one of the strips breaks, thereby producing the audible sound. The strips may include a weakened portion such as a narrowing. Integrity of the package is indicated by an intact strip viewable upon opening the resealable closure and conversely, a broken or non-intact strip would indicate that the resealable closure has been previously opened. Package integrity may also be shown by a movable second panel or movable die cut tab portions.
For covid-19 patients, cytokine storms are a major reason that some require intensive care and ventilation, said Jeffrey Weber, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center.
Date: Apr 15, 2020
Category: More news
Source: Google
New clinical trial might change the standard treatment for melanoma
Results like this will change how we practice medicine, said Jeffrey Weber, a professor of medicine at NYU Langone School of Medicine, who presented the findings at the annual meeting of the European Society for Medical Oncology in Madrid. The results were published simultaneously online in the Ne
"This is clearly an outstanding science result that sets the scene for the further development of the test to quantify [immune biomarkers] in different malignancies," said Dr. Jeffrey Weber, an immunologist and oncologist at the Moffitt Cancer Center in Tampa, Fla., who was
"It's the first in a series of targeted drugs, meaning it's a drug that targets a specific mutation in about half of all melanomas that begin on the skin," said Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center at the H. Lee Moffitt Cancer Center. "It's really imp
Date: Aug 21, 2011
Category: Health
Source: Google
New melanoma drug had trial run at Moffitt Cancer Center
Dr. Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt, was an investigator on a Phase II student that enrolled 132 patients. The study showed that vemurafenib (pronounced vem-yoo-RAF-en-ib) shrank tumors in 52 percent of trial participants, and participa
University of Louisville - Electrical Engineering, Atherton High School
About:
I now own my own company Frozen Mercury Productions, I hope it's the start of something amazing. I am a jack of all trades I know something about everything, and am willing to share all my knowled...
Tagline:
Jeffrey Arra Weber
Jeffrey Weber
Work:
Booz Allen Hamilton
Education:
Virginia Polytechnic Institute and State University
Jeffrey Weber
Education:
McCluer North High School
Relationship:
Married
Jeffrey Weber
Tagline:
G-Code
Jeffrey Weber
Jeffrey Weber
Jeffrey Weber
Jeffrey Weber
Youtube
Cancer Revealed: How the Immune System Sees a...
On June 16, 2015, Jeffrey S. Weber, M.D., Ph.D., discussed the cancer ...
Duration:
1h 2m 36s
Meet Oncologist Dr. Jeffrey Weber
NYU Langone oncologist Dr. Jeffrey Weber is a specialist in melanoma m...
Duration:
2m 21s
Dr Jeffrey Weber explains his approach to imm...
Drs Jeffrey Weber and Khalid Jazieh discuss immunotherapy-in... colit...
Duration:
10m 9s
How to manage chronic non-cutaneous immune-re...
Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, disc...
Duration:
5m 25s
Jeffrey Weber Explains Organ-Specific Side Ef...
Jeffrey Weber, MD, PhD, from NYU Langone Perlmutter Cancer Center expl...
Duration:
1m 51s
Dr. Jeffrey Weber on Optimal Therapy Sequence...
Jeffrey S. Weber, MD, PhD, the director of the Donald A. Adam Comprehe...